Synergistic Uterine Fibroid Treatment System

A novel, integrated system combining collagenase-based treatment with AI, IoT, blockchain, and advanced materials to revolutionize uterine fibroid treatment, enhancing efficacy, personalization, and patient data management.

The original patent disclosed a method for treating uterine fibroids using purified collagenase. However, this treatment approach has limitations, such as lack of real-time visualization, limited patient data management, and restricted delivery methods. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful, comprehensive system.

The Synergistic Uterine Fibroid Treatment System comprises several interconnected modules. The collagenase composition delivery module administers the purified collagenase to the uterine fibroid. The AI-powered imaging module provides real-time fibroid visualization, enabling precise treatment monitoring. The blockchain-based patient data management system securely stores and analyzes patient data, ensuring confidentiality and facilitating personalized treatment planning. IoT-enabled sensors track fibroid size reduction, and machine learning algorithms analyze treatment outcomes. The system also incorporates biocompatible, 3D-printed matrices for targeted delivery and nanocarrier systems for enhanced bioavailability. Genetic testing and machine learning-based treatment planning modules enable personalized treatment approaches.

The new claims introduce a synergistic combination of technologies, creating a novel system that overcomes the limitations of the original patent. The integration of AI, IoT, blockchain, and advanced materials with collagenase-based treatment represents a non-obvious, innovative step in uterine fibroid treatment.

Alternative embodiments may include variations in the AI-powered imaging module, such as using different imaging modalities or incorporating additional sensors. The blockchain-based patient data management system could be replaced with alternative secure data storage solutions. The collagenase composition delivery module could be modified to accommodate different delivery methods or matrices.

The Synergistic Uterine Fibroid Treatment System has significant commercial potential in the medical device and pharmaceutical industries, addressing a high-incidence, high-burden disease affecting millions of women worldwide. The system's personalized approach, enhanced efficacy, and improved patient data management capabilities position it for market success.